Jihyoun Lee1, Ho Hur2, Jong Won Lee3, Hyun Jo Youn4, Kyungdo Han5, Nam Won Kim1, So-Youn Jung6, Zisun Kim7, Ku Sang Kim8, Min Hyuk Lee1, Se-Hwan Han9, Sung Hoo Jung4, Il Yong Chung3. 1. Department of Surgery, Soonchunhyang University Seoul Hospital, Seoul, Korea. 2. Department of Surgery, National Health Insurance Service Ilsan Hospital, Goyang-Si, Korea. 3. Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. 4. Department of Surgery, Chonbuk National University Hospital, Jeonju-Si, Korea. 5. Department of Biostatistics, College of Medicine, Catholic University of Korea, Seoul, Korea. 6. Breast Cancer Center, National Cancer Center, Goyang, Korea. 7. Department of Surgery, Soonchunhyang University College of Medicine, Bucheon, Korea. 8. Department of Breast-Thyroid Surgery, Dongkang Medical Center, Ulsan, Korea. 9. Department of Surgery, Ajou University, School of Medicine, Suwon, Korea.
Abstract
BACKGROUND: There is a controversy about late-onset congestive heart failure (CHF) among breast cancer survivors. This study investigated the incidence rate and risk factors of late-onset CHF more than 2 years after the breast cancer diagnosis. METHODS: A nationwide, retrospective study was conducted with the National Health Information Database. With 1:3 age- and sex-matched noncancer controls, Cox proportional hazard regression models were used to analyze the incidence and risk factors of late CHF. The cumulative incidence rate of late CHF was evaluated with a Kaplan-Meier analysis and a log-rank test. RESULTS: A total of 91,227 cases (286,480 person-years) and 273,681 controls (884,349 person-years) were evaluated between January 2007 and December 2013. The risks of late CHF were higher in cases than controls (hazard ratio [HR], 1.396; 95% confidence interval [CI], 1.268-1.538). Younger survivors (age ≤ 50 years) showed a higher risk of late CHF than their younger counterparts (HR, 2.903; 95% CI, 2.425-3.474). Although older age was a risk factor for late CHF, older survivors (age ≥ 66 years) showed no difference in the risk of late CHF in comparison with their counterparts (HR, 0.906; 95% CI, 0.757-1.084). Anthracyclines and taxanes were risk factors for late CHF, although trastuzumab, radiation, and endocrine therapy were not. CONCLUSIONS: Young breast cancer survivors have a greater risk of late CHF than the young population without cancer. More attention should be paid to young breast cancer survivors who receive taxane- or anthracycline-based regimens over the long term.
BACKGROUND: There is a controversy about late-onset congestive heart failure (CHF) among breast cancer survivors. This study investigated the incidence rate and risk factors of late-onset CHF more than 2 years after the breast cancer diagnosis. METHODS: A nationwide, retrospective study was conducted with the National Health Information Database. With 1:3 age- and sex-matched noncancer controls, Cox proportional hazard regression models were used to analyze the incidence and risk factors of late CHF. The cumulative incidence rate of late CHF was evaluated with a Kaplan-Meier analysis and a log-rank test. RESULTS: A total of 91,227 cases (286,480 person-years) and 273,681 controls (884,349 person-years) were evaluated between January 2007 and December 2013. The risks of late CHF were higher in cases than controls (hazard ratio [HR], 1.396; 95% confidence interval [CI], 1.268-1.538). Younger survivors (age ≤ 50 years) showed a higher risk of late CHF than their younger counterparts (HR, 2.903; 95% CI, 2.425-3.474). Although older age was a risk factor for late CHF, older survivors (age ≥ 66 years) showed no difference in the risk of late CHF in comparison with their counterparts (HR, 0.906; 95% CI, 0.757-1.084). Anthracyclines and taxanes were risk factors for late CHF, although trastuzumab, radiation, and endocrine therapy were not. CONCLUSIONS: Young breast cancer survivors have a greater risk of late CHF than the young population without cancer. More attention should be paid to young breast cancer survivors who receive taxane- or anthracycline-based regimens over the long term.
Authors: Nathalie I Bouwer; Agnes Jager; Crista Liesting; Marcel J M Kofflard; Jasper J Brugts; Jos J E M Kitzen; Eric Boersma; Mark-David Levin Journal: Breast Date: 2020-04-16 Impact factor: 4.380
Authors: Muzna Hussain; Yuan Hou; Chris Watson; Rohit Moudgil; Chirag Shah; Jame Abraham; G Thomas Budd; W H Wilson Tang; J Emanuel Finet; Karen James; Jerry D Estep; Bo Xu; Bo Hu; Paul Cremer; Christine Jellis; Richard A Grimm; Neil Greenberg; Zoran B Popovic; Leslie Cho; Milind Y Desai; Steven E Nissen; Samir R Kapadia; Lars G Svensson; Brian P Griffin; Feixiong Cheng; Patrick Collier Journal: Am J Cardiol Date: 2020-09-28 Impact factor: 2.778
Authors: Yadi Zhou; Yuan Hou; Muzna Hussain; Sherry-Ann Brown; Thomas Budd; W H Wilson Tang; Jame Abraham; Bo Xu; Chirag Shah; Rohit Moudgil; Zoran Popovic; Leslie Cho; Mohamed Kanj; Chris Watson; Brian Griffin; Mina K Chung; Samir Kapadia; Lars Svensson; Patrick Collier; Feixiong Cheng Journal: J Am Heart Assoc Date: 2020-11-26 Impact factor: 5.501